AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

F011 - Where Do We Stand? The Pathogenesis and Treatment of Melasma

Description

The presentation focuses on melasma, a multifactorial skin disorder impacting emotional well-being and quality of life, particularly in individuals with phototypes 3 to 5. Misdiagnosis can occur in lighter phototypes, where patient histories often reveal misdiagnosed iatrogenic melasma due to aggressive treatments. Understanding melasma's pathogenesis is essential, as it behaves similarly to an inflammatory disorder, influenced by factors like hormonal changes, UV exposure, and inflammation. Effective treatment often requires combination therapy because topical remedies only provide partial relief. The use of low-energy and picosecond lasers is emphasized for their ability to effectively target dermal melanin with minimal inflammation, alongside topical agents that suppress pigment production. Case examples demonstrate significant treatment success using these methods, with recommendations for protective measures against hyperpigmentation. Future treatment innovations in laser technology aim to enhance targeting of melanophages without impacting surrounding tissues. Overall, a thorough understanding of melasma is crucial for achieving optimal patient outcomes in treatment.

View more

Conclusions

  • Melasma is a multifactorial disorder that significantly impacts quality of life, particularly in patients with phototype III, IV, and V skin.
  • Misdiagnosis of melasma can occur, especially in patients with lower phototypes, leading to incorrect treatments.
  • A comprehensive patient history is crucial for accurate diagnosis and understanding triggers of melasma.
  • Melasma exhibits high melanin production and involvement of dermal melanophages, behaving more like an inflammatory disorder.
  • Effective treatment of melasma requires a combination of therapies targeting different pathologic factors, including topicals and laser treatments.
  • The use of low-energy nanosecond and picosecond lasers is effective in treating melasma and achieving long-term remission with minimal adverse effects.
  • Combination treatments involving pigmented and vascular lasers can enhance melasma treatment outcomes, especially for patients with vascular components.
  • 4-6 weeks of topical agents and a cautious approach to laser therapy can prevent complications like hyperpigmentation in susceptible patients.
  • Novel 3D focused laser technologies may offer improved targeting for treating melasma while minimizing damage to surrounding tissues.
  • Kauvar AN. Lasers Surg Med. 2012 Feb;44(2):117-24.
  • Kauvar AN. Semin Cutan Med Surg. 2012 Jun;31(2):126-32.
  • Manuskiatti W, Yan C, Tantrapornpong P. et al. Lasers Surg Med. 2021 Jan;53(1):95-103.
  • Passeron T, Fontas E, Young Kang H, et al. Arch Dermatol. 2011 Sep;147(9):1106-8.
  • Passeron T. J Am Acad Dermatol. 2013 Sept;69(3):e141-2.
  • Geddes E, Stout A, Friedman P. Retrospective analysis of the treatment of melasma lesions exhibiting increased vascularity with the 595-nm pulsed dye laser combined with the 1927-nm fractional low-powered diode laser.
  • Chan NP, Ho SG, Yeung CK, Shek SY, Chan HH. Lasers Surg Med. 2010 Oct;42(8):712-9.
  • Cohen and Ross. J Clin Aesthet Dermatol. 2015 8(9): 48-53.